Entrada Therapeutics Inc. has received authorization from the U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee (REC) for its CTIMP (clinical trial of an investigational medicinal product) application for a phase I clinical trial in healthy volunteers for ENTR-601-44.